Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02681328 · ClinicalTrials.gov registry record
Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules
A clinical trial of Thyroid, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- 328
- Enrollment target
- 1
- Study location
NCT02681328 is a study of Thyroid that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 328 participants, above the 279-participant average among 5 other Thyroid trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02681328, a study of Thyroid, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 328 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life. In the initial phase of this study, the performance of Afirma GEC and ThyroSeq v.2 were compared.
Conditions Studied
Interventions
- OTHER Afirma GEC
- OTHER ThyroSeq v.2
- OTHER Afirma GSC
- OTHER ThyroSeq v.3
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02681328
The ClinicalTrials.gov registry entry for NCT02681328 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 279-participant average among 5 other Thyroid trials with a reported enrollment target (18% higher). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid appearing as the primary indexed condition, and to 4 interventions - of which Afirma GEC is the first listed.
NCT02681328 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02681328 about?
NCT02681328 is a clinical study titled "Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules". The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life. In the initial phase of this study, the performance of Afirma GEC and Thy...
What is the current status of trial NCT02681328?
This trial is currently active not recruiting. The enrollment target is 328 participants. The study started on 2016-05-01. Estimated completion is 2027-12-01.
What conditions does trial NCT02681328 study?
This clinical trial studies the following conditions: Thyroid.
What interventions are being tested in trial NCT02681328?
The interventions under investigation include: Afirma GEC (OTHER), ThyroSeq v.2 (OTHER), Afirma GSC (OTHER), ThyroSeq v.3 (OTHER).
Who is sponsoring clinical trial NCT02681328?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02681328 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of ARDS With Instilled T3
RECRUITING · Phase 2
-
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
RECRUITING
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
Laser Ablation of Papillary Thyroid Microcarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Gene Hunting Study for Familial Papillary Thyroid Cancer
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.